Document:

<PAGE>

                                                                     Exhibit 4.2

                                 LOAN AGREEMENT

         THIS LOAN AGREEMENT is dated and entered into as of June 22, 2001 (the
"Effective Date") by and between PILOT THERAPEUTICS, INC., a North Carolina
corporation ("Borrower"), and PHARMABIO DEVELOPMENT INC., a North Carolina
corporation ("Lender").

         WHEREAS, Borrower and Lender are parties to an Investment and Royalty
Agreement (the "Investment Agreement"), dated as of the same date hereof;

         WHEREAS, in connection with the Investment Agreement, Lender is willing
to extend certain credit facilities to Borrower, subject to and upon the terms
and conditions of this Agreement; and

         WHEREAS, Borrower and Innovex LP, an Affiliate of Lender, are parties
to a Commercialization Agreement (the "Commercialization Agreement"), dated as
of the date hereof;

         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged by the parties, the parties hereby
agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

         1.01 Definitions. Capitalized terms used but not defined in the text of
this Agreement shall have the meanings ascribed to them on Exhibit A attached
hereto and incorporated herein by reference.

                                   ARTICLE II
                            AMOUNT AND TERMS OF LOAN

         2.01 Advances.

                  (a) Subject to and upon the terms and conditions set forth
herein, Lender agrees, at any time and from time to time from the date of this
Agreement to and including June 22, 2004 (as extended pursuant to Section 2.07,
the "Maturity Date"), to make advances (each an "Advance" and collectively the
"Advances") to Borrower at such times and in such amounts as Borrower shall
request pursuant to this Agreement, up to an aggregate principal amount of Two
Million Dollars ($2,000,000) (as adjusted in accordance with Sections 2.01(b)
and (c), the "Commitment") in lawful money of the United States of America in
immediately available funds; the entire initial amount of the Commitment shall
be disbursed to Borrower concurrently with the execution of this Agreement.
<PAGE>

                  (b) If the "Pre-Launch Sales Forecast" prepared by the "JMC"
as provided in Section 3.3 of the Investment Agreement projects that annual peak
sales will be at least Seventy Million Dollars ($70,000,000) for any "Annual
Period" in the "Royalty Term" (all such terms as defined in the Investment
Agreement), then the Commitment shall be increased to Four Million Dollars
($4,000,000) in the aggregate.

                  (c) If (i) the "Pre-Launch Sales Forecast" prepared by the
"JMC" as provided in Section 3.3 of the Investment Agreement projects that
annual peak sales will be at least Seventy Million Dollars ($70,000,000) for any
"Annual Period" in the "Royalty Term" (all such terms as defined in the
Investment Agreement), and (ii) a Qualified Financing (as defined below) has
occurred, then the Commitment shall be increased to Six Million Dollars
($6,000,000) in the aggregate.

                  (d) Borrower may use the Commitment, as in effect from time to
time, on a revolving basis by borrowing, repaying the Advances in whole or in
part, and reborrowing, all in accordance with the terms and conditions of this
Agreement; provided that the aggregate amount of the Advances at any time shall
not exceed the Commitment as in effect at such time. It is the intention of the
parties that the aggregate outstanding principal amount of the Advances not be
greater than the Commitment, as in effect from time to time. If at any time, the
aggregate outstanding principal amount of the Advances exceeds the Commitment,
Borrower shall promptly pay to Lender in cash the amount of such excess.

                  (e) Each Advance shall be a principal amount of a loan,
evidenced by the Note (as defined in Section 2.05).

                  (f) Notwithstanding anything to the contrary in this
Agreement, in the event a Change of Control occurs, Lender may elect to
terminate any obligation hereunder to make any additional Advances by giving
written notice to Pilot upon the earlier of (i) the date on which the Change of
Control occurs or (ii) within ten (10) business days after Lender receives
written notice that the Change of Control has or is expected to occur. If Lender
makes such election, (x) Borrower shall not request any additional Advances and
(y) Lender's purchase rights under Section 2.07(b) shall be adjusted such that
the maximum dollar amount that it may convert or purchase pursuant to Section
2.07 shall equal the aggregate amount of Advances made at any time on or prior
to the date of Lender's election, plus interest and fees accrued thereon, not to
exceed $6,000,000.

         2.02 Use of Proceeds. The Advances shall be used solely for working
capital and general corporate purposes.

         2.03 Notices of Advances; Disbursement of Funds.

                  (a) Whenever Borrower desires to obtain an Advance, Borrower
shall give to Lender a written notice of the requested Advance, signed by an
officer of Borrower (each a "Notice of Advance"), and received no later than
3:00 p.m. Eastern Time three (3) Business Days before the day on which Borrower
desires the Advance to be made. The Notice of Advance shall specify: (i) the
aggregate principal amount of the Advance to be made; (ii) the

                                       2
<PAGE>

date on which Borrower desires the Advance to be made, which date shall be a
Business Day; and (iii) an account of Borrower to which the Advance shall be
directed and wire transfer instructions. In any event, the giving of each Notice
of Advance shall constitute a representation and warranty by Borrower to Lender
that the conditions precedent set forth in Section 3.02 have been satisfied.

                  (b) Whenever Borrower desires to obtain an Advance, Lender
shall make available to Borrower, at an account of Borrower specified to Lender
by an officer of Borrower, no later than 2:00 p.m. Eastern Time on the date
specified in the Notice of Advance for such Advance, the aggregate amount of
such requested Advance. Each Notice of Advance requesting an Advance shall be
irrevocable when sent by Borrower, unless otherwise agreed by Lender.

                  (c) The amount of each Advance shall not be less than
$250,000.

         2.04 Advances Made. On the date specified in each Notice of Advance, an
Advance shall be made under the Note in accordance with Section 2.03(b).

         2.05 Note. Borrower's obligation to pay the principal of, and interest
on, the Advances made by Lender shall be evidenced by a single promissory note
(the "Note") duly executed and delivered by Borrower in the form of Exhibit B
attached hereto. All Advances made by Lender to Borrower, and all payments in
respect thereof (and all reborrowings thereof, if any), shall be recorded by
Lender and shall be endorsed on the grid attached to the Note. Failure to make
any such notation shall not affect Borrower's obligations in respect of such
Advances unless such failure is willful. Borrower shall have fifteen (15) days
after receipt from time to time of the updated grid attached to the Note to
object to any record of notation made by Lender thereon and, in such case, such
grid shall not be presumed accurate until Borrower and Lender so agree.

         2.06 Repayment; Interest; Fees.

                  (a) Borrower shall pay the aggregate outstanding principal
balance of, and all accrued interest on, all Advances on or before the Maturity
Date. Borrower may prepay any Advance or any accrued interest on Advances at any
time and from time to time prior to the Maturity Date without penalty and
without consent of Lender, on the following terms and conditions: (i) Borrower
shall give Lender at least three (3) Business Days' prior notice of its intent
to prepay and the amount of the prepayment and (ii) each prepayment shall not be
less than $250,000.

                  (b) Borrower agrees to pay interest in respect of the unpaid
principal amount of each Advance from the date the proceeds are received by, and
made available to, Borrower until repaid. Interest on the outstanding principal
amount of each Advance shall accrue and be payable at a rate per annum equal to
the greater of (i) ten percent (10%) or (ii) two and one-half percent (2.5%) in
excess of the Prime Rate in effect from time to time (the "Base Rate"), or, if
less, the maximum rate permitted by law. Interest shall be calculated on the
basis of a 360-day year for the actual number of days elapsed.

                                       3
<PAGE>

                  (c) Accrued interest shall be due and payable (i) in respect
of each Advance, quarterly in arrears on the last Business Day of each calendar
quarter (each, an "Interest Payment Date"), and (ii) upon any payment of
principal, on the amount paid. Notwithstanding the foregoing, Borrower may elect
on a quarterly basis, by written notice to the Lender at least three (3)
Business Days prior to the due date of such interest, to defer the repayment of
accrued interest. Any such amount of deferred interest shall be deemed an
Advance pursuant to Section 2.01, shall be recorded on the Note in accordance
with Section 2.05, and shall accrue interest in accordance with this Section
2.06.

                  (d) Borrower agrees to pay to Lender commitment fees as
follows:

                           (i) $20,000, payable on the first anniversary of the
date of this Agreement;

                           (ii) $20,000, payable on the first anniversary of the
date on which the Commitment is increased from $2,000,000 to $4,000,000 (if
applicable) as described in Section 2.01 above; and

                           (iii) $20,000, payable on the first anniversary of
the date on which the Commitment is increased from $4,000,000 to $6,000,000 (if
applicable) as described in Section 2.01 above.

         The date on which any of the amounts set forth in this Section 2.06(d)
is due is hereinafter referred to as a "Commitment Fee Payment Date."

                  (e) The outstanding principal amount of an Advance or any
accrued interest amounts thereon or any commitment fees that are not paid when
due shall accrue interest (after any applicable cure period) on a daily basis at
the lesser of (i) three percent (3%) in excess of the Base Rate, or (ii) the
maximum rate permitted by law, such accrual beginning on the date payment is due
and continuing until the date payment is made in full. Except as provided in
this Section 2.06(e), and except as provided in Section 2.06(c) regarding
deferred interest, no accrued interest shall bear or accrue interest.

                  (f) All payments of principal, interest and fees described
above shall be made to Lender in lawful money of the United States of America in
immediately available funds.

         2.07 Conversion and Purchase Rights.

                  (a) At any time and from time to time on or before the
Maturity Date, Lender shall have the right and option to convert, in whole or in
part (i) upon written notice from Lender to Borrower at least ten (10) days
prior to the applicable Interest Payment Date or Commitment Fee Payment Date, as
the case may be, the accrued interest (including deferred interest) on the
Advances under the Note and the commitment fees referred to in Section 2.06,
into shares of common stock of Borrower ("Common Stock"); and (ii) upon written
notice from Lender to Borrower on or before the Maturity Date, the outstanding
principal amount of any Advances; provided in the case of clause (ii), that if
Lender does not give the notice at least sixty (60) days

                                       4
<PAGE>

prior to the Maturity Date, then (A) the Maturity Date shall be extended by
sixty (60) days, less the number of days prior to the Maturity Date that Lender
gives Borrower written notice that Lender will not be converting, and (B) no
further interest shall accrue pursuant to this Agreement or the Note for the
period beginning on the original Maturity Date (i.e., without giving effect to
the foregoing extension) and ending on the new Maturity Date (i.e., as
extended). The number of shares of Common Stock into which such interest, fees
or principal may be converted shall be equal to the aggregate amount being
converted, divided by the Conversion Price (as determined pursuant to this
Section 2.07).

                  (b) On or before the Maturity Date, Lender shall have the
right and option to purchase up to an aggregate number of shares of Common Stock
equal to: the positive excess, if any, of (i) the aggregate dollar amount of the
Commitment at such time (regardless, except as set forth in Section 2.01(f), of
whether there are any outstanding Advances) over (ii) the aggregate principal
amount theretofore converted or thereafter convertible pursuant to Section
2.07(a) above, divided by the Conversion Price; such purchase to be consummated
on a mutually acceptable date within thirty (30) days after the Maturity Date.
In connection with such purchase, Lender agrees to deliver to Borrower customary
investor representations and warranties including to the effect that Lender is
an "accredited investor" as defined under Rule 501 promulgated under the
Securities Act of 1933, as amended (the "Securities Act"). The maximum dollar
amount that may be converted or purchased pursuant to this Section 2.07 shall be
Six Million Dollars ($6,000,000) in the aggregate, subject to adjustment
pursuant to Section 2.01(f)(y).

                  (c) "Conversion Price" shall be determined as follows:

                           (i) If a Threshold Transaction (as defined in this
Section 2.07) occurs on or before December 31, 2001, then the "Conversion Price"
shall be:

                                    (x) $5.00 per share with respect to any
                  amount being converted pursuant to Section 2.07(a) or any
                  amount being purchased pursuant to Section 2.07(b), up to an
                  aggregate amount equal to $3,000,000; and

                                    (y) with respect to any amount being so
                  converted or purchased in excess of the amount described in
                  clause (x) above, 70% of (A) the purchase price per share in a
                  Qualified Financing (as defined in this Section 2.07) or (B)
                  the value of the shares of stock or other securities or
                  property (including cash) attributable in a Qualified
                  Acquisition (as defined in this Section 2.07) to, or received
                  or to be received in a Qualified Acquisition in respect of,
                  one (1) share of Common Stock; provided that the Conversion
                  Price pursuant to Section 2.07(c)(i)(y) shall not be less than
                  the highest conversion price of Borrower's preferred stock
                  under its Amended and Restated Articles of Incorporation, as
                  may be amended and in effect from time to time (the "Borrower
                  Articles"), unless, at any time after the date of this
                  Agreement, Borrower has issued (or, contemporaneously with a
                  conversion or purchase by Lender hereunder, Borrower issues)
                  any shares of capital stock at a purchase price below the
                  highest conversion price of Borrower's preferred stock under
                  the Borrower Articles

                                       5
<PAGE>

                  triggering an unwaived conversion price adjustment for any
                  series of Borrower's preferred stock. Notwithstanding the
                  foregoing proviso, in the event that the Borrower Articles are
                  amended after the date hereof, Borrower will use reasonable
                  commercial efforts to exclude the conversion and purchase
                  features herein from the anti-dilution provisions of the
                  Borrower Articles and, if so excluded, then such proviso shall
                  not be applicable.

                           (ii) If a Threshold Transaction does not occur on or
before December 31, 2001, the "Conversion Price" shall be $3.83.

                           (iii) In the event of an Acquisition Transaction, the
unexercised conversion and purchase rights of Lender hereunder shall survive
such Acquisition Transaction (including with respect to the Commitment and
Advances, and interest and fees related thereto, which are assigned or made
available to such Acquiring Person) and shall become conversion and purchase
rights with respect to the common stock of the Acquiring Person (which shall be
thereafter deemed "Common Stock" hereunder). In such event and notwithstanding
Section 2.07(c)(i)(y)(B), Lender and Borrower shall execute an amendment to this
Section 2.07 effective as of the closing of such Acquisition Transaction, which
shall establish a new Conversion Price applicable to the common stock of the
Acquiring Person (the "New Conversion Price") and which shall make any other
changes to this Section 2.07 reasonably necessary to reflect and address the
terms of this Section 2.07(c)(iii). Borrower and Lender agree that such
amendment and the New Conversion Price are intended to afford Lender the
benefits of Section 2.07(c)(i) with respect to the common stock of the Acquiring
Person, taking into account (A) the number of shares of Borrower Common Stock
which Lender would have been able to obtain by conversion or purchase
immediately prior to the closing of such Acquisition Transaction and (B) the
Conversion Price at such time after giving effect to the Acquisition
Transaction. In the event that, after diligent, good faith efforts, Borrower and
Lender are not able to agree on a New Conversion Price, the New Conversion Price
shall be resolved and established pursuant to the provisions of Section 13 of
the Investment Agreement (regarding Dispute Resolution).

                           (iv) If Borrower (or Acquiring Person) at any time
shall subdivide or combine its Common Stock, effect a recapitalization or
reclassification of its Common Stock, or effect or engage in any similar event
or transaction (other than as provided for in clause (iii) above), then the
Conversion Price shall be proportionately adjusted to account therefor.

                           (v) Except as provided for in clause (iii) above, if
the Common Stock shall be changed into, or exchanged for, the same or a
different number of shares of any other class or classes of stock, whether by
reorganization, reclassification or otherwise, including in connection with any
merger, share exchange, business combination or other similar transaction, or
the sale of all or substantially all of the assets of Borrower (other than as
provided for in clause (iii) above), then concurrently with the effectiveness of
such event, the conversion and purchase provisions of this Section 2.07 shall be
proportionately adjusted so that Lender shall have the right to convert into, or
purchase, a number of shares of such other class or classes of stock equivalent
to the number of shares of Common Stock that would have been subject to
conversion or purchase by Lender immediately before such event.

                                       6
<PAGE>

                           (vi) Borrower will not, by amendment of the Borrower
Articles or through any reorganization, recapitalization, merger, consolidation,
transfer of assets, dissolution, issue or sale of securities, or any other
action, avoid or seek to avoid the observance or performance of any of the terms
of this Section 2.07, but will at all times in good faith assist in carrying out
all the provisions of this Section 2.07 and in taking all such action as be
necessary or appropriate in order to protect the rights of Lender against
impairment.

                           (vii) "Threshold Transaction" shall mean the first to
occur of (x) the closing after the date of this Agreement of the sale by
Borrower (or an Acquiring Person) of shares of its capital stock for an
aggregate purchase price of $10,000,000 to one or more to venture capital,
institutional, corporate or other accredited investors (so long as accredited
investors who are individuals account for less that 50% of such purchase price)
in a single transaction or a series of related transactions (a "Qualified
Financing") or (y) a merger, consolidation, share exchange, business
combination, reorganization or other similar transaction involving Borrower, or
the sale or other transfer of all or substantially all of the assets of
Borrower, in each case unless the shareholders of Borrower immediately prior to
such transaction hold greater than fifty percent (50%) of the combined voting
power of the outstanding securities of the surviving, continuing or acquiring
entity in such transaction (a "Qualified Acquisition"). The determination of
"combined voting power" shall be based on the aggregate number of votes that are
attributable to outstanding securities entitled to vote in the election of
directors, general partners, managers or persons performing analogous functions
to directors of the entity in question, without regard to contractual
arrangements that establish a management structure or that vest the right to
designate directors in certain parties.

                  (d) Borrower shall, as soon as reasonably practicable after
the valid exercise of Lender's rights by Lender under this Section 2.07 and the
satisfaction of all conditions to such exercise of rights, issue and deliver to
Lender a certificate or certificates for the number of shares of Common Stock to
which Lender is entitled upon conversion or purchase pursuant to this Section
2.07 (including, without limitation, delivery of the purchase price in the event
of a purchase).

                  (e) Borrower shall at all times reserve and keep available out
of its authorized but unissued shares of Common Stock, solely for the purpose of
effecting the conversion or purchase pursuant to Sections 2.07(a) or 2.07(b),
such number of its shares of Common Stock as shall from time to time be
sufficient to effect such conversion or purchase; and if at any time the number
of authorized but unissued shares of Common Stock shall not be sufficient to
effect such conversion, in addition to such other remedies as shall be available
to Lender, Borrower shall use its best efforts to take such corporate action as
may be necessary to increase its authorized but unissued shares of Common Stock
to such number of shares as shall be sufficient for such purposes.

                  (f) Lender shall have the registration rights and benefits
afforded to "Registration Rights Holders" in respect of "Registrable Securities"
under Section 1.4 (regarding certain "piggy-back" registration rights) of the
Amended and Restated Investor Rights Agreement dated as of February 28, 2001
among Borrower and certain holders of its capital stock (including any
continuation, successor, replacement, restatement or reconstitution thereof,

                                       7
<PAGE>

the "Rights Agreement") in respect of all shares of Common Stock of Borrower
acquired by Lender pursuant to this Agreement; provided that Lender (i) complies
with all of the obligations required to be complied with by "Registration Rights
Holders" under the Rights Agreement in respect of such rights and benefits, (ii)
hereby acknowledges that its right to include shares of Common Stock in a
registration shall be limited to the extent that the inclusion of such
securities will not diminish the amount of "Registrable Securities" (as defined
therein) which may be included in such registration in accordance with Section
1.10 of the Rights Agreement (or any substantially similar provision of a
continued, successor, replacement, restated or reconstituted Rights Agreement)
and (iii) hereby agrees to be bound by the terms of Section 1.13 of the Rights
Agreement (or any substantially similar provision of a continued, successor,
replacement, restated or reconstituted Rights Agreement).

                  (g) With a view to making available the benefits of certain
rules and regulations of the Securities and Exchange Commission (the
"Commission") that may permit the sale of the shares of Common Stock acquired
hereunder to the public without registration, Borrower agrees to use its best
efforts to:

                           (i) make and keep public information regarding
Borrower available as those terms are understood and defined in Rule 144 under
the Securities Act, at all times from and after 90 days following the effective
date of the first registration under the Securities Act filed by Borrower for an
offering of its securities to the general public;

                           (ii) file with the Commission in a timely manner all
reports and other documents required of Borrower under the Securities Act and
the Exchange Act at any time after it has become subject to such reporting
requirements; and

                           (iii) so long as Lender owns any shares, furnish to
Lender forthwith upon written request as to Borrower's compliance with the
reporting requirements of Rule 144 (at any time from and after 90 days following
the effective date of the first registration statement filed by Borrower for an
offering of its securities to the general public), and of the Securities Act and
the Exchange Act (at any time after it has become subject to such reporting
requirements), a copy of the most recent annual or quarterly report of Borrower.

                                   ARTICLE III
                              CONDITIONS PRECEDENT

         3.01 Initial Conditions Precedent to Lender's Obligations. The
obligation of Lender to perform its obligations under this Agreement is subject
to the conditions precedent that Lender shall have received from Borrower each
of the following executed documents on the date of this Agreement:

                  (a) The Note in the form of Exhibit B attached hereto;

                  (b) The Security Agreement in the form of Exhibit C attached
hereto (the "Security Agreement"), pursuant to which Borrower will grant to
Lender a security interest in

                                       8
<PAGE>

the Collateral as security for the Note and the other obligations of Borrower
under this Agreement; and acknowledgement copies of proper financing statements
(e.g., Form UCC-1) duly filed pursuant to the Uniform Commercial Code in the
offices of the Secretary of State of North Carolina and Forsyth County, North
Carolina;

                  (c) Copies of (i) resolutions of the Board of Directors of
Borrower approving this Agreement, the Note, and the Security Agreement and any
other documents required or necessary to consummate the transactions
contemplated in this Loan Agreement (collectively, the "Loan Documents"), the
Investment Agreement and the Commercialization Agreement, (ii) the Borrower
Articles, and (iii) the Amended and Restated Bylaws of Borrower, in each case
certified by an appropriate officer of Borrower;

                  (d) A certificate of the appropriate officers of Borrower
certifying (i) the names and true signatures of the officers of Borrower
authorized to sign the Loan Documents, the Investment Agreement and the
Commercialization Agreement, (ii) that the representations and warranties
contained in Article IV of this Agreement are true and correct as of the date
hereof, and (iii) that no event has occurred and is continuing, which
constitutes an Event of Default (as defined in Section 7.01 hereof) or would
constitute an Event of Default but for the requirement that notice be given or
time elapse or both; and

                  (e) A legal opinion of Womble Carlyle Sandridge & Rice PLLC,
counsel for Borrower, regarding the Loan Documents and the transactions
contemplated thereby in the form of Exhibit D attached hereto.

         3.02 Conditions Precedent to All Advances. The obligation of Lender to
make each Advance shall be subject to the further conditions precedent that, on
the date of such Advance:

                  (a) The representations and warranties contained in Sections
4.05, 4.07, 4.08, 4.11 and 4.12 of this Agreement are true and correct on and as
of the date of such Advance, before and after giving effect to such Advance and
to the application of the proceeds therefrom, as though made on and as of such
date;

                  (b) No event has occurred and is continuing, or would result
from such Advance or from the application of the proceeds therefrom, which
constitutes an Event of Default, or would constitute an Event of Default but for
the requirement that notice be given or time elapse or both or that obligations
of Borrower under the Loan Documents be outstanding as required in Section 7.01;
and

                  (c) All accrued interest or commitment fees under this
Agreement which are due and payable at such time shall have been paid in full
(subject to any interest deferral rights of Borrower hereunder).

                                       9
<PAGE>

                                   ARTICLE IV
                         REPRESENTATIONS AND WARRANTIES
                                   OF BORROWER

         Borrower represents and warrants to Lender as follows:

         4.01 Corporate Status; Subsidiaries. Borrower is a corporation duly
incorporated, validly existing and in good standing under the laws of the State
of North Carolina, and has all requisite corporate power and authority to own
and use its properties and assets and to transact the business in which it is
currently engaged. The only subsidiaries of the Company are Pilot
Pharmaceuticals Corporation and Pilot Nutraceuticals Corporation, each of which
is wholly owned and neither of which has engaged in any business operations.

         4.02 Corporate Power and Authority. The execution and delivery by
Borrower of the Loan Documents, the Investment Agreement and the
Commercialization Agreement, the performance of the terms and obligations
therein, and the issuance, sale and delivery of the Common Stock issuable
pursuant to Section 2.07 are each within Borrower's corporate powers and have
been duly authorized by all necessary corporate action on the part of Borrower.
The Loan Documents, the Investment Agreement and the Commercialization Agreement
constitute valid and legally binding obligations of Borrower enforceable against
Borrower in accordance with their terms.

         4.03 Approvals and Consents. No authorization, consent, approval or
other action by, and no notice to or filing with, any governmental authority or
regulatory body, or any other party, is required or necessary for the valid
execution, delivery and performance by Borrower of the Loan Documents, the
Investment Agreement or the Commercialization Agreement, where the failure to
obtain any such authorization, consent, approval or other action or the failure
to so notify or file, would have a material adverse effect on Borrower.

         4.04 Capitalization. (a) The authorized capital of Borrower consists
of:

                           (i) 2,556,580 shares of Preferred Stock, of which (A)
750,000 shares have been designated Series A Preferred Stock, all of which are
issued and outstanding as of the date of this Agreement, (B) 1,566,580 have been
designated Series B Preferred Stock, of which 934,419 shares are issued and
outstanding as of the date of this Agreement, and (C) 250,000 are undesignated,
none of which are outstanding as of the date of this Agreement; and

                           (ii) 10,000,000 shares of Common Stock, of which
2,018,785 shares are issued and outstanding as of the date of this Agreement.

                  (b) Except (i) for the conversion privileges of the Preferred
Stock, (ii) for outstanding stock options and warrants as of the date hereof,
(iii) as provided in the Borrower Articles and Borrower's Amended and Restated
Investor Rights Agreement, in each case as may be amended from time to time, and
(iv) for a conditional option that may be granted to Century Capital Associates,
LLC as provided in its agreement with Borrower dated March 8, 2000 to purchase
an aggregate of 15,000 shares of Common Stock, there are no outstanding options,

                                       10
<PAGE>

warrants, rights, or agreements of any kind for the purchase or acquisition from
Borrower of any of its securities as of the date of this Agreement.

         4.05 No Violation. Neither the execution or delivery by Borrower of the
Loan Documents, the Investment Agreement and the Commercialization Agreement,
nor the performance of their respective terms and obligations, will (i) violate
Borrower's charter or bylaws, (ii) constitute a breach or default under any
agreement or instrument to which Borrower is a party or by which Borrower is
bound, which breach or default would have a material adverse effect on Borrower,
(iii) violate any applicable law, rule or regulation, which violation would have
a material adverse effect on Borrower, or (iv) violate any order, writ,
injunction, decree or judgment of any court or governmental authority applicable
to or binding on Borrower, which violation would have a material adverse effect
on Borrower.

         4.06 Financial Statements; Budget and Projections.

                  (a) Borrower has delivered to Lender a draft of its Financial
Statements (balance sheet and profit and loss statement, statement of
shareholder's equity and statement of cash flows including notes thereto) at
December 31, 2000 and for the fiscal year then ended and its unaudited Financial
Statements (balance sheet and profit and loss statement) as at, and for the four
month period ended, April 30, 2001 (the "Financial Statements"). The Financial
Statements have been prepared in accordance with generally accepted accounting
principles applied on a consistent basis throughout the periods indicated and
with each other, except that they may not contain all footnotes required by
generally accepted accounting principles. The Financial Statements fairly
present the financial condition and operating results of Borrower as of the
dates, and for the periods, indicated therein, subject to normal year-end audit
adjustments and the absence of footnotes. Except to set forth in the Financial
Statements, the Borrower has no material liabilities, contingent or otherwise,
other than (i) liabilities incurred in the ordinary course of business
subsequent to the most recent Financial Statements and (ii) obligations under
contracts and commitments incurred in the ordinary course of business and not
required under generally accepted accounting principles to be reflected in the
Financial Statements, which, in both cases, individually or in the aggregate,
are not material to the financial condition or operating results of Borrower.
Since the date of the most recent Financial Statements, there has been no
material adverse change of Borrower. Borrower maintains and will continue to
maintain a standard system of accounting established and administered in
accordance with generally accepted accounting principles. Promptly upon Borrower
obtaining its audited financial statements for the year ended December 31, 2000,
Borrower will deliver such financial statements to Lender.

                  (b) Borrower has furnished Lender with a summary of Borrower's
financial budget and financial projections for its fiscal year ending December
31, 2001. Such financial budget and financial projections are reasonable and
consistent with Borrower's current and historical performance and its Financial
Statements. Borrower has furnished to Lender all projections, estimates,
forecasts and similar materials prepared by Borrower or its advisors regarding
the Product.

                                       11
<PAGE>

         4.07 Litigation. There is no pending, or to Borrower's knowledge
threatened, action, suit, proceeding, arbitration, or investigation before any
court, governmental agency, instrumentality or arbitrator, which, if determined
adversely to Borrower or its subsidiaries, could reasonably be expected to have
a material adverse effect on Borrower and its subsidiaries or which purports to
affect the legality, validity or enforceability of the Loan Documents, the
Commercialization Agreement or the Investment Agreement.

         4.08 Valid Issuance. Upon Borrower's issuance of any and all shares of
Common Stock pursuant to Section 2.07, such shares of Common Stock shall be duly
authorized, validly issued, fully paid, non-assessable and free and clear of all
Liens, except for restrictions imposed by the securities laws and except for
liens created by Lender.

         4.09 Compliance with Laws, etc. Each of Borrower and its subsidiaries
is in compliance with all applicable laws, rules, regulations and orders of, and
all applicable restrictions imposed by, all governmental bodies, in respect of
the conduct of its business and the ownership of its property, except where the
failure to be in compliance would not have a material adverse effect on Borrower
and its subsidiaries; provided, that no subsidiary of Borrower conducts business
or owns property as of the date hereof.

         4.10 Tax Returns and Payments. Each of Borrower and its subsidiaries
has, to Borrower's knowledge, filed all federal, state, local, foreign and other
tax returns required to be filed by it and has paid all taxes and other
assessments which have become due pursuant to such tax returns and all other
taxes and assessments which have become due, except for those contested in good
faith and for which adequate reserves have been established. Each of Borrower
and its subsidiaries has made adequate provisions on its books of account for
all taxes, assessments and governmental charges with respect to its business,
properties and operations for all prior fiscal years and for the current fiscal
year to the date hereof. No governmental authority has asserted a Lien or other
claim against Borrower or any of its subsidiaries with respect to unpaid taxes
which has not been discharged or resolved, which would have a material adverse
effect on Borrower and its subsidiaries.

         4.11 Insurance. Each of Borrower and its subsidiaries maintains
insurance on all of its properties with financially sound and reputable
insurance companies against such risks and in such amounts as are customarily
maintained by companies of comparable size engaged in a similar business;
provided that no subsidiary of Borrower engages in business or maintains any
insurance as of the date hereof.

         4.12 Intellectual Property.

         (a) Borrower owns or has a valid right to use, license or otherwise
exploit, free and clear of all Liens, all Intellectual Property (i) necessary or
used by Borrower to conduct its business in the manner in which it has been and
is being conducted and in the manner in which its business is contemplated to be
conducted by the Loan Documents, Commercialization Agreement and Investment
Agreement and (ii) necessary to enable the Company or used by the Company to
develop, commercialize, manufacture, market and sell, and obtain applicable
regulatory or governmental approval, if any, with respect to, the Product
(collectively,

                                       12
<PAGE>

"Company Intellectual Property"), except (i) that the Company has not yet
secured a license with respect to the oral anti-acne drug (PLT 99511), (ii) that
those patent and patent applications relating to CoA-IT inhibitors are jointly
owned by Wake Forest University ("WFU") or Johns Hopkins University ("JHU") and
SmithKline Beecham and the Company has licensed only the rights of WFU and JHU
with respect thereto, and (iii) to the extent the patent rights of WFU or JHU
are deemed to infringe upon the rights of a third party. Borrower licenses
Company Intellectual Property pursuant to the License Agreement between Borrower
and WFU dated December 11, 1998 and the License Agreement between Borrower and
JHU dated May 5, 1999, in each case as may be amended from time to time.

         (b) Borrower has no knowledge of any facts or circumstances that would
render any Company Intellectual Property invalid or unenforceable. Without
limiting the foregoing, Borrower knows of no information, materials, facts, or
circumstances, including any information or fact that would constitute prior
art, that would render any of the Company Intellectual Property invalid or
unenforceable, or would adversely effect any pending application for any Company
Intellectual Property, and Borrower has not misrepresented, or failed to
disclose, and has no knowledge of any misrepresentation or failure to disclose,
any facts or circumstances in any application for any Company Intellectual
Property that would constitute a misrepresentation with respect to such
application or that would otherwise affect the validity or enforceability of any
Company Intellectual Property. Borrower has no knowledge of any facts or
circumstances related to the Company Intellectual Property that would prevent or
adversely affect the successful development and commercialization of the
Product.

         (c) Notwithstanding the exceptions in Section 4.12(a), to the knowledge
of Borrower, the Company Intellectual Property and the products or devices that
have been developed or manufactured by Borrower, and any apparatus or processes
used by Borrower in the manufacture thereof, do not and will not infringe,
misappropriate or make any unauthorized use of any Intellectual Property owned
or used by any other party. Borrower has received no notice or other
communication (in writing or otherwise) of any actual, alleged or potential
infringement, misappropriation or unauthorized use of, any Intellectual Property
owned or used by any other party. No Company Intellectual Property is subject to
any proceeding or outstanding decree, order, judgment or settlement agreement
that restricts in any manner the use, transfer, licensing or enforceability
thereof by Borrower. No event or circumstance has occurred which permits (or
after notice or lapse of time or both would permit) the revocation or
termination of any of the Company Intellectual Property. Borrower has no
knowledge of any facts or circumstances that any other party has been or is
infringing, misappropriating or making any unauthorized use of any Company
Intellectual Property.

         4.13 Debt. As of the date of this Agreement, no Debt is outstanding for
or owed by Borrower, except for Debt to leasing companies with respect to assets
held by Borrower under capital leases.

         4.14 Liens. As of the date of this Agreement, no Lien exists upon or
with respect to any of Borrower's properties or assets, except for Liens held by
leasing companies with respect to assets held by Borrower under capital leases.

                                       13
<PAGE>

         4.15 Disclosure. Neither this Agreement nor any other agreements,
written statements or certificates made or delivered by or on behalf of Borrower
in connection herewith contain or will contain any untrue statement of a
material fact or omits to state a material fact necessary in order to make the
statements herein or therein not misleading.

                                    ARTICLE V
                    REPRESENTATIONS AND WARRANTIES OF LENDER

         Lender hereby represents and warrants to Borrower as follows:

         5.01 Corporate Status. Lender is a corporation duly incorporated,
validly existing and in good standing under the laws of the State of North
Carolina, and has all requisite corporate power and authority to own and use its
properties and assets and to transact the business in which it is currently
engaged.

         5.02 Corporate Power and Authority. The execution and delivery by
Lender of the Loan Documents, and the performance of the terms and obligations
therein, are each within Lender's corporate powers, and each has been duly
authorized by all necessary corporate action. The Loan Documents, when executed
and delivered hereunder, will constitute valid and legally binding obligations
of Lender enforceable against Lender in accordance with their terms.

         5.03 Approvals and Consents. No authorization, consent, approval or
other action by, and no notice to or filing with, any governmental authority or
regulatory body, or any other party, is required or necessary for the valid
execution, delivery and performance by Lender of the Loan Documents or the
Investment Agreement where the failure to obtain any such authorization,
consent, approval or other action or the failure to so notify or file, would
have a material adverse effect on the benefit to be derived by Borrower under
this Agreement.

         5.04 No Violation. Neither the execution or delivery by Lender of the
Loan Documents or the Investment Agreement, nor the performance of their
respective terms and obligations, will (i) violate Lender's charter or bylaws,
(ii) constitute a breach or default under any agreement or instrument to which
Lender is a party or by which Lender is bound, which breach or default would
have a material adverse effect on the benefit to be derived by Borrower under
this Agreement, (iii) violate any applicable law, rule or regulation, which
violation would have a material adverse effect on the benefit to be derived by
Borrower under this Agreement, or (iv) violate any order, writ, injunction,
decree or judgment of any court or governmental authority applicable to or
binding on Lender, which violation would have a material adverse effect on the
benefit to be derived by Borrower under this Agreement.

         5.05 Litigation. There is no pending, or to Lender's knowledge
threatened, action, suit, proceeding, arbitration, or investigation before any
court, governmental agency, instrumentality or arbitrator, which, if determined
adversely to Lender, could reasonably be expected to have a material adverse
effect on the benefit to be derived by Borrower under this Agreement or which
purports to affect the legality, validity or enforceability of the Loan
Documents, Commercialization Agreement or Investment Agreement.

                                       14
<PAGE>

         5.06 Accredited Investor. Lender is an "accredited investor" as defined
in Rule 501(a) of Regulation D, as promulgated under the Securities Act of 1933,
as amended, because it is a corporation not formed for the specific purpose of
acquiring the Note or shares of Common Stock into which the Note is convertible
or that are purchasable hereunder, with total assets in excess of $5,000,000.

         5.07 Disclosure. Neither this Agreement nor any other agreements,
written statements or certificates made or delivered by or on behalf of Lender
in connection herewith contain or will contain any untrue statement of a
material fact or omits to state a material fact necessary in order to make the
statements herein or therein not misleading.

                                   ARTICLE VI
                              COVENANTS OF BORROWER

         So long as any or all of the Notes shall remain unpaid or Lender shall
have any Commitment hereunder, Borrower shall comply with the following
covenants:

         6.01 Compliance with Laws. Borrower shall comply, and cause each of its
subsidiaries to comply, with all applicable laws, rules, regulations and orders,
where the failure to so comply would have a material adverse effect on Borrower
and its subsidiaries, such compliance to include without limitation paying
before the same become delinquent all taxes, assessments and governmental
charges imposed upon it or upon its property except to the extent contested in
good faith.

         6.02 Transfers of Assets. Except in connection with a permitted
assignment of this Agreement under Section 8.06, Borrower shall not sell,
convey, transfer, lease, license, assign or otherwise dispose of (whether in one
transaction or in a series of transactions) (a) the Collateral, except to the
extent permitted by the Security Agreement, or (b) Borrower's right, title and
interest in and to the Covered Intellectual Property, in each case until such
time as the Commitment has been terminated and all obligations of Borrower under
the Loan Documents with respect to Advances or otherwise have been irrevocably
paid and satisfied in full. Notwithstanding anything herein or in the Security
Agreement to the contrary, Borrower may grant bona fide commercial licenses for
the Covered Intellectual Property or the Company Intellectual Property in the
ordinary course of Borrower's business on commercially reasonable terms.

         6.03 Debt. Borrower shall not create or allow to be created or exist,
or permit any of its subsidiaries to create or allow to be created or exist, any
Debt, except (a) Debt created in the ordinary course of Borrower's business and
which does not exceed $500,000 in the aggregate, and (b) Borrower may create
Debt which is junior and subordinate in right of payment to Borrower's
obligations to Lender under the Loan Documents ("Junior Debt") so long as, prior
to the creation of such Junior Debt, Lender has consented in writing to such
Junior Debt and Lender and the holder of such Junior Debt have entered into a
subordination agreement in form and

                                       15
<PAGE>

substance satisfactory to the Lender providing for the subordination of the
Junior Debt to the obligations of Borrower under the Loan Documents.

         6.04 Liens, Etc. Borrower shall not create or allow to be created or
exist, or permit any of its subsidiaries to create or allow to be created or
exist, any Lien upon or with respect to any of the Collateral or the Covered
Intellectual Property until such time as the Commitment has been terminated and
all obligations of Borrower under the Loan Documents with respect to Advances or
otherwise have been irrevocably paid and satisfied in full, except (a) Liens
with respect to capital leases described in Section 4.14, (b) additional Liens
incurred in the ordinary course of Borrower's business and which secure Debt
that does not exceed $500,000 in the aggregate, and (c) Borrower may create
Liens securing indebtedness which is junior and subordinate in right of payment
to Borrower's obligations to Lender under the Loan Documents ("Junior Liens") so
long as, prior to the creation of such Junior Liens, Lender has consented in
writing to such Junior Liens and Lender and the holder of such Junior Liens have
entered into a subordination agreement in form and substance satisfactory to the
Lender providing for the subordination of the indebtedness secured by the Junior
Liens to the obligations of Borrower under the Loan Documents.

         6.05 Corporate Existence. Borrower will maintain and preserve in full
force and effect its corporate existence.

         6.06 Financial Information. Borrower will provide to Lender:

                  (a) As soon as practicable after the end of each fiscal year
of Borrower, and in any event within ninety (90) days thereafter, an audited
consolidated balance sheet of the Borrower and its subsidiaries, if any, as at
the end of such fiscal year, and consolidated statements of income and cash
flows of the Borrower and its subsidiaries, if any, for such year, prepared in
accordance with generally accepted accounting principles consistently applied
and setting forth in each case in comparative form the figures for the previous
fiscal year, all in reasonable detail and certified by independent public
accountants of recognized national or regional standing selected by the
Borrower; and

                  (b) As soon as practicable after the end of the first, second,
and third quarterly accounting periods in each fiscal year of the Borrower, and
in any event within forty-five (45) days thereafter, an unaudited consolidated
balance sheet of the Borrower and its subsidiaries, if any, as of the end of
each such quarterly period, and consolidated statements of income and cash flows
of the Borrower and its subsidiaries, if any, for such period and for the
current fiscal year to date, prepared in accordance with generally accepted
accounting principles consistently applied (except for the absence of footnotes
and customary year-end audit adjustments) and setting forth in comparative form
the figures for the corresponding periods of the previous fiscal year, subject
to changes resulting from normal year-end audit adjustments, all in reasonable
detail and certified by the principal financial or accounting officer of the
Borrower.

                  (c) Annually (and in any event promptly after adoption by the
Board of Directors of Borrower) the financial plan of Borrower, in such manner
and form as approved by the Board of Directors of Borrower, which financial plan
shall include at least a projection of

                                       16
<PAGE>

income and projected cash flow statement for each fiscal quarter in such fiscal
year and a projected balance sheet as of the end of each fiscal quarter in such
fiscal year; provided, that Lender acknowledges that such projections are not
intended and shall not be deemed to guaranty the future operations of Borrower.
Any material changes to such financial plan shall be delivered to Lender
promptly after such changes have been approved by the Board of Directors of
Borrower.

                  (d) In the event Borrower becomes a wholly owned subsidiary of
a corporate parent, as a result of a corporate restructuring or otherwise, all
references to Borrower under this 6.06 shall be deemed references to such
corporate parent.

         6.07 Change of Control Notice. In the event that Borrower shall at any
time propose or have knowledge of a proposed or actual Change of Control or
Acquisition Transaction, Borrower will promptly notify Lender thereof in
writing.

                                   ARTICLE VII
                                EVENTS OF DEFAULT

         7.01 Events of Default. At any time at which any obligations of the
Borrower are outstanding under the Loan Documents with respect to any Advances,
the occurrence of each of the following events shall be considered an event of
default ("Event of Default"):

                  (a) Borrower shall fail to pay any principal of, or interest
on, the Note within five (5) days after receipt of notice from Lender that the
same has become due and payable;

                  (b) Any representation or warranty made by Borrower under or
in connection with this Agreement shall prove to have been incorrect when made
or deemed made and is not cured within thirty (30) days of receipt of notice by
Borrower from Lender;

                  (c) Borrower shall fail to perform or observe any term,
covenant or agreement contained in this Agreement required to be performed or
observed by Borrower (other than Section 6.02, 6.03 or 6.04) and is not cured
within thirty (30) days after receipt of notice by Borrower from Lender;

                  (d) Borrower shall fail to perform or observe the provisions
of Section 6.02, 6.03 or 6.04 above;

                  (e) One or more judgments or orders for the payment of money
shall be entered against Borrower or any of its subsidiaries involving in the
aggregate a liability of $250,000 or more, and each such judgment or order shall
continue without discharge or stay for a period of thirty (30) days;

                  (f) Borrower shall (i) commence a voluntary case under the
federal bankruptcy laws (as now or hereafter in effect), (ii) file a petition
seeking to take advantage of any other laws relating to bankruptcy, insolvency,
reorganization, winding up or composition for

                                       17
<PAGE>

adjustment of debts, (iii) consent to or fail to contest in a timely and
appropriate manner any petition filed against it in an involuntary case under
such bankruptcy laws or other laws, (iv) apply for or consent to, or fail to
contest in a timely and appropriate manner, the appointment of, or the taking of
possession by, a receiver, custodian, trustee, or liquidator of itself or of a
substantial part of its property, (v) admit in writing its inability to pay its
debts as they become due, (vi) make a general assignment for the benefit of
creditors, or (vii) take any corporate action for the purpose of authorizing any
of the foregoing;

                  (g) A case or other proceeding shall be commenced against
Borrower or any of its subsidiaries in any court of competent jurisdiction
seeking (i) relief under the federal bankruptcy laws (as now or hereafter in
effect) or under any other laws relating to bankruptcy, insolvency,
reorganization, winding up or adjustment of debts, or (ii) the appointment of a
trustee, receiver, custodian, liquidator or the like for Borrower or any of its
subsidiaries or for all or any substantial part of their respective assets, and
such case or proceeding shall continue without dismissal or stay for a period of
thirty (30) consecutive days, or an order granting the relief requested in such
case or proceeding (including, but not limited to, an order for relief under
such federal bankruptcy laws) shall be entered;

                  (h) A Change of Control shall occur, which has not been
approved by at least two-thirds of the directors of Borrower;

                  (i) Borrower or any of its subsidiaries shall default in the
performance or observance of any agreement or instrument relating to any Debt,
or any other event shall occur or condition exist, and the effect of such
default, event or condition is to cause or permit the holder of any such Debt to
cause any such Debt to become due prior to its stated maturity;

                  (j) Lender shall terminate the Investment Agreement under
Section 7.0 thereof;

                  (k) the Borrower shall fail to perform or observe any term,
covenant or agreement under the Security Agreement in any material respect; or

                  (l) the License Agreement between Wake Forest University and
Borrower dated December 11, 1998 shall have been terminated.

         7.02 Effect of Default. If any Event of Default shall occur and be
continuing, then Lender (i) may, by notice to Borrower, declare the Commitment
and its obligation to make Advances to be terminated, whereupon the same shall
forthwith terminate, and (ii) may, by notice to Borrower, declare the Note, all
interest thereon and all other amounts payable under this Agreement to be
forthwith due and payable, whereupon the Note, all such interest and all such
amounts shall become and be forthwith due and payable, without presentment,
demand, protest or further notice of any kind, all of which are hereby expressly
waived by Borrower; provided, however, that if an Event of Default specified in
Section 7.01(f) and (g) shall occur, (A) the Commitment and the obligation of
Lender to make Advances shall automatically be terminated and (B) the Note, all
such interest and all such amounts shall automatically become

                                       18
<PAGE>

and be due and payable, without presentment, demand, protest or any notice of
any kind, all of which are hereby expressly waived by Borrower.

         7.03 Other Events. In the event (i) of a Change of Control in which all
or substantially all of the consideration to be received by Borrower or its
shareholders consists of cash, (ii) Borrower sells, transfers or otherwise
disposes of assets or rights representing or relating to a line of its business
or a material portion of the Company Intellectual Property (provided that
without limiting clause (i), this clause (ii) shall not apply to (A) a sale,
transfer or disposal of all or substantially all of the assets of Borrower, (B)
a disposition in which the shareholders of Borrower immediately before such
disposition own at least 51% of the combined voting power or of the outstanding
equity securities of the acquiring entity or (C) a bona fide commercial license
for Company Intellectual Property in the ordinary course of Borrower's business
on commercially reasonable terms) or (iii) Borrower is not using commercially
reasonable efforts to develop and commercialize the Product, then Lender shall
have all of the same rights that it would have in an Event of Default under
Section 7.02 and the Security Agreement.

                                  ARTICLE VIII
                                  MISCELLANEOUS

         8.01 Amendments. No amendment or waiver of any provision of this
Agreement or the Notes, nor consent to any departure by Borrower therefrom,
shall in any event be effective unless the same shall be in writing and signed
by Borrower and Lender, and then such waiver or consent shall be effective only
in the specific instance and for the specific purpose for which given.

         8.02 Notices. All notices and other communications provided for
hereunder shall be in writing, shall specifically refer to this Agreement, shall
be addressed to the receiving party's address set forth below or to such other
address as a party may designate by notice hereunder, and shall be deemed to
have been sufficiently given for all purposes if (i) mailed by first class
certified or registered mail, postage prepaid, (ii) sent by express delivery
service, (iii) personally delivered, or (iv) made by telecopy or facsimile
transmission with confirmed receipt.

         If to Borrower:   Pilot Therapeutics, Inc.
                           101 North Chestnut Street
                           Albert Hall
                           Winston-Salem, NC 27101
                           Attn: Chief Executive Officer
                           Facsimile: 336-725-2221

         with a copy to:   Womble Carlyle Sandridge & Rice PLLC
                           200 West Second Street
                           Winston-Salem, NC 27101
                           Attn: Peter A. Zorn
                           Facsimile: 336-726-6906

                                       19
<PAGE>

         If to Lender:     PharmaBio Development Inc.
                           4709 Creekstone Drive
                           Riverbirch Bldg., Suite 200
                           Durham, NC 27703
                           Attn: Tom Perkins
                           Facsimile:(919) 998-2090

         with a copy to:   L. Stephen Garlow
                           General Counsel
                           Innovex, Inc.
                           10 Waterview Boulevard
                           Parsippany, NJ 07054
                           Facsimile:(973) 257-4581

         with a copy to:   Smith, Anderson, Blount, Dorsett, Mitchell &
                                Jernigan, L.L.P.
                           2500 First Union Capitol Center
                           Raleigh, NC 27601
                           Attn: Christopher B. Capel
                           Facsimile: (919) 821-6800

         8.03 No Waiver; Remedies. No failure on the part of Lender to exercise,
and no delay in exercising, any right hereunder or under the Notes shall operate
as a waiver thereof; nor shall any single or partial exercise of any such right
preclude any other or further exercise thereof or the exercise of any other
right. The remedies herein provided are cumulative and not exclusive of any
remedies provided by law.

         8.04 Right of Set-off. If an Event of Default shall have occurred and
be continuing, Lender is hereby authorized at any time and from time to time, to
the fullest extent permitted by law, to set off and apply any payment obligation
by Lender to Borrower under the Investment Agreement or Commercialization
Agreement against any and all of the obligations of Borrower now or hereafter
existing under this Agreement and the Note, whether or not Lender shall have
made any demand under this Agreement or the Note and although such obligations
may be unmatured. Lender agrees promptly to notify Borrower after any such
set-off and application, provided that the failure to give such notice shall not
affect the validity of such set-off and application. The rights of Lender under
this Section 8.04 are in addition to other rights and remedies (including,
without limitation, other rights of set-off) which Lender may have.

         8.05 Attorneys' Fees. In the event that any dispute among the parties
to this Agreement should result in litigation, the prevailing party in such
dispute shall be entitled to recover from the losing party all fees, costs and
expenses enforcing any right of such prevailing party under or with respect to
this Agreement, including without limitation, such reasonable fees and expenses
of attorneys and accountants, which shall include, without limitation, all fees,
costs and expense of appeals.

                                       20
<PAGE>

         8.06 Binding Effect; Assignment. This Agreement shall be binding upon
and inure to the benefit of Borrower and Lender and their respective successors
and assigns, provided that neither Borrower nor Lender may assign or transfer
any or all of its rights or obligations under the Loan Documents without the
prior written consent of the other party not to be unreasonably withheld;
provided however, that (i) Lender may at any time assign or transfer any or all
of its rights or obligations under the Loan Documents to an Affiliate, (ii)
Borrower may at any time assign or transfer any or all of its rights or
obligations under the Loan Documents to an Affiliate; provided, however, that
notwithstanding any such transfer or assignment Borrower hereby agrees to
satisfy and fulfill all such obligations, the same as if it remained a party to
the Loan Documents, and (iii) Borrower may assign or transfer any or all of its
rights or obligations under the Loan Documents as part of (A) the sale of all or
substantially all of its nutraceutical business to a bona fide third party so
long as the Investment Agreement is also assigned to such party in connection
therewith or (B) as part of a merger, consolidation, share exchange or similar
transaction in which it is not the surviving or continuing entity, other than a
cash transaction described in Section 7.03(i).

         8.07 Governing Law; Consent to Jurisdiction. This Agreement and the
Notes shall be governed by, and construed in accordance with, the laws of the
State of North Carolina, without reference to the conflicts or choice of law
principals thereof. Borrower and Lender hereby irrevocably consents to the
exclusive personal jurisdiction of any state or federal courts located in North
Carolina, in any action, claim or other proceeding arising out of any dispute in
connection with the Loan Documents, any rights or obligations hereunder or the
performance of such rights and obligations. Lender and Borrower agree to waive
their respective rights to a jury trial with respect to any action, claim, or
other proceeding arising out of any dispute in connection with the Loan
Documents, the Investment Agreement or the Commercialization Agreement, any
rights or obligations hereunder or thereunder, or the performance of such rights
and obligations.

         8.08 Severability. To the extent any provision of this Agreement is
prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this
Agreement.

         8.09 Entire Agreement. This Agreement, the other Loan Documents, the
Investment Agreement and the Commercialization Agreement embody the entire
agreement and understanding between the parties hereto and supersede all prior
oral or written agreements and understandings relating to the subject matter
hereof. No statement, representation, warranty, covenant or agreement of any
kind not expressly set forth in the Loan Documents (or the Investment Agreement
or Commercialization Agreement) shall affect, or be used to interpret, change or
restrict, the express terms and provisions of the Loan Documents.

         8.10 Further Action. Each party shall, without further consideration,
take such further action and execute and deliver such further documents as may
be reasonably requested by the other party in order to carry out the provisions
and purposes of this Agreement.

                                       21
<PAGE>

         8.11 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original and all of which,
when taken together, shall constitute one and the same instrument.

                     [REST OF PAGE INTENTIONALLY LEFT BLANK;
                          SIGNATURES ON FOLLOWING PAGE]

                                       22
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Loan Agreement
to be executed by their respective officers thereunto duly authorized, as of the
date first above written.

                                            BORROWER:

                                            PILOT THERAPEUTICS, INC.

                                            By: /s/Floyd H. Chilton
                                                -------------------
                                            Name: Floyd H. Chilton
                                            Title: CEO

                                            LENDER:

                                            PHARMABIO DEVELOPMENT INC.

                                            By: /s/ Tom Perkins
                                               ----------------
                                            Name: Tom Perkins
                                            Title: VP & General Counsel

                                       23
<PAGE>

                                    EXHIBIT A
                                   DEFINITIONS

         "Affiliate" shall have the meaning given such term in Rule 12b-2 of the
Exchange Act.

         "Acquiring Person" shall mean the surviving, continuing or acquiring
entity in an Acquisition Transaction.

         "Acquisition Transaction" shall mean the occurrence of any of the
following events: (i) Borrower shall merge or consolidate (or engage in any
other share exchange, acquisition or business combination transaction) with or
into another corporation or entity, (ii) the acquisition of all or substantially
all of the Common Stock of Borrower, (iii) Borrower shall sell, convey,
transfer, lease, license, assign or otherwise dispose of all or substantially
all of its assets to any person or entity, or (iv) Borrower shall sell all or
substantially all of its nutraceutical business as described in Section 8.06.

         "Agreement" or "Loan Agreement" shall mean this Loan Agreement between
Lender and Borrower.

         "Business Day" shall mean any day other than a Saturday, Sunday or
legal holiday on which banks in North Carolina are open for the conduct of their
banking business.

         "Change of Control" shall mean the occurrence of any of the following
events: (i) the acquisition, whether directly or indirectly, by any person or
entity, including a "group" as defined in Section 13(d)(3) of the Exchange Act,
of more than fifty-one percent (51%) of the Common Stock of Borrower; (ii)
Borrower shall merge or consolidate (or engage in any other share exchange,
acquisition or business combination transaction) with or into another
corporation or other entity; (iii) Borrower shall sell, convey, transfer, lease,
license, assign or otherwise dispose of (whether in one transaction or a series
of transactions) all or substantially all of its assets (whether now owned or
hereafter acquired) to any person or entity, or permit any of its subsidiaries
to do so; or (iv) at any time during any calendar year, fifty percent (50%) or
more of the members of the full Board of Directors of Borrower shall have
resigned or been removed or replaced; provided, that, (A) in the case of clauses
(i)-(iii), the persons who were the shareholders of Borrower immediately prior
to the effective time of such transaction hold less than fifty-one percent (51%)
of the combined voting power or of the outstanding equity securities of all of
the surviving, continuing and acquiring entities in such transaction (as
applicable) and (B) in the case of clause (iv), fewer than fifty percent (50%)
of the members of the full Board of Directors of Borrower immediately prior to
the transaction serve on the Boards of Directors (or analogous body of a
noncorporate entity) of all of the surviving, continuing and acquiring entities
(as applicable). The determination of "combined voting power" shall be based on
the aggregate number of votes that are attributable to outstanding securities
entitled to vote in the election of directors, general partners, managers or
persons performing analogous functions to directors of the entity in question,
without regard to contractual arrangements that establish a management structure
or that vest the right to designate directors in certain parties.

         "Collateral" shall have the meaning given such term in the Security
Agreement.
<PAGE>

         "Covered Intellectual Property" shall have the meaning given such term
in the Security Agreement.

         "Debt" shall mean (i) indebtedness for borrowed money, (ii) obligations
evidenced by bonds, debentures, notes or other similar instruments, (iii)
obligations to pay the deferred purchase price of property or services, (iv)
obligations as lessee under leases which shall have been or should be, in
accordance with generally accepted accounting principles, recorded as capital
leases, and (v) obligations under direct or indirect guaranties in respect of,
and obligations (contingent or otherwise) to purchase or otherwise acquire, or
otherwise to assure a creditor against loss in respect of, indebtedness or
obligations of others of the kinds referred to in clauses (i) through (iv)
above.

         "Intellectual Property" shall mean all: trade, business and product
names; trademarks; service marks; copyrights; patents; discoveries; trade
secrets; business and technical information; proprietary compilations of data or
information; know-how; inventions; formulas and techniques; methods; regulatory
filings; computer software; all intellectual property rights, registrations,
licenses and applications pertaining to any of the foregoing; and all related
documentation and goodwill.

         "Liens" shall mean any lien, security interest, mortgage, pledge,
encumbrance, charge or claim.

         "Material adverse effect" or "material adverse change" on or of
Borrower shall mean a material adverse effect or change on or of the properties,
assets, operations, financial condition, results of operations or prospects of
the Borrower and its subsidiaries.

         "Prime Rate" shall mean the rate which First Union National Bank (or
its successor) announces from time to time as its prime lending rate, the Prime
Rate to change when and as such prime lending rate changes.

         "Product" shall have the meaning given such term in the Investment
Agreement; provided that for purposes of any representation or warranty made by
Borrower with respect to the Product, such representation or warranty shall be
deemed to be made as to the Product as it exists at the time of such
representation or warranty.<PAGE>

                                                                    Exhibit 4.3

                               SECURITY AGREEMENT

THIS SECURITY AGREEMENT (this "Agreement") is dated and entered into as of June
22, 2001, by and between PILOT THERAPEUTICS, Inc., a North Carolina corporation
("Borrower"), and PHARMABIO DEVELOPMENT INC., a North Carolina corporation
("Lender"). WITNESSETH:

         WHEREAS, Borrower and Lender are parties to a Loan Agreement (as
amended, modified or supplemented from time to time, the "Loan Agreement") dated
as of the same date hereof, pursuant to which, among other things, Borrower is
delivering to Lender the Note (as defined in the Loan Agreement); and

         WHEREAS, it is a condition precedent to the performance of Lender under
the Loan Agreement that Borrower enter into this Agreement;

         NOW, THEREFORE, in consideration of the benefits to Borrower, the
receipt and legal sufficiency of which are hereby acknowledged, Borrower hereby
makes the following representations and warranties to Lender and hereby
covenants and agrees with Lender as follows:

         1. Definitions. The following terms, as used in this Agreement, shall
have the following meanings:

         "Collateral" shall mean all monies, Contract Rights, Contracts, General
Intangibles, Instruments, Payment Intangibles, Promissory Notes and Receivables,
relating to or arising out of or in connection with any sale, lease, license,
conveyance, transfer or disposition of any right, title or interest in, to or
under the Product or the Covered Intellectual Property, and all Proceeds of any
and all of the foregoing, but excluding the Product itself and the Covered
Intellectual Property itself.

         "Contracts" shall mean all contracts, agreements and licenses between
Borrower and one or more other parties.

         "Contract Rights" shall mean all rights of Borrower (including, without
 limitation, all rights to payment) under each Contract.

         "Covered Intellectual Property" shall mean any and all Intellectual
 Property which is embodied, used or included in, or which otherwise comprises
 or constitutes, the Product.

         "General Intangible" shall mean "general intangible" as such term is
 defined in the Uniform Commercial Code as in effect on the date hereof and as
 in effect from time to time in the State of North Carolina.

         "Intellectual Property" shall have the meaning given to such term under
the Loan Agreement.
<PAGE>

         "Instrument" shall mean "instrument" as such term is defined in the
Uniform Commercial Code as in effect on the date hereof and as in effect from
time to time in the State of North Carolina.

         "License Agreement" shall mean the License Agreement between Borrower
and Wake Forest University dated December 11, 1998, as may be amended from time
to time.

         "Liens" shall mean any lien, security interest, mortgage, pledge or
encumbrance.

         "Obligations" shall mean all indebtedness, obligations and liabilities
of Borrower to Lender arising under or in connection with the Note (as defined
in the Loan Agreement) and under or in connection with each of the Loan
Agreement and the Security Documents.

         "Payment Intangible" shall mean "payment intangible" as such term is
defined in the Uniform Commercial Code as in effect on the date hereof and as in
effect from time to time in the State of North Carolina.

         "Proceeds" shall mean "proceeds," "cash proceeds" and "noncash
proceeds" as such terms are defined in the Uniform Commercial Code as in effect
on the date hereof and as in effect from time to time in the State of North
Carolina.

         "Product" shall have the meaning given to such term under the Loan
Agreement.

         "Promissory Note" shall mean "promissory note" as such term is defined
in the Uniform Commercial Code as in effect on the date hereof and as in effect
from time to time in the State of North Carolina.

         "Receivable" shall mean any "account" as such term is defined in the
Uniform Commercial Code as in effect on the date hereof and as in effect from
time to time in the State of North Carolina, and, in any event, shall include,
but shall not be limited to, all of Borrower's rights to payment for goods sold,
leased or licensed or services performed by Borrower, whether now in existence
or arising from time to time hereafter, including, without limitation, rights
evidenced by an account, note, contract, security agreement, chattel paper or
other evidence of indebtedness or security, together with (a) all security
pledged, assigned, hypothecated or granted to or held by Borrower to secure the
foregoing, (b) all of Borrower's right, title and interest in and to any goods,
the sale of which gave rise thereto, (c) all guarantees, endorsements and
indemnifications on, or of, any of the foregoing, (d) all powers of attorney for
the execution of any evidence of indebtedness or security or other writing in
connection therewith, (e) all books, records, ledger cards, and invoices
relating thereto, (f) all evidences of the filing of financing statements and
other statements and the registration of other instruments in connection
therewith and amendments thereto, notices to other creditors or secured parties,
and certificates from filing or other registration officers, (g) all credit
information, reports and memoranda relating thereto and (h) all other writings
related in any way to the foregoing.

                                       2
<PAGE>

          "Security Documents" shall mean, collectively, this Agreement and the
financing statements and security interest filing statements described herein.

          2. Grant of Security Interests. (a) As security for the prompt and
complete payment and performance of all of the Obligations, Borrower does hereby
assign, transfer, pledge, and hypothecate unto Lender, and does hereby grant to
Lender a continuing security interest of first priority in, all of the right,
title, and interest of Borrower in, to, and under the Collateral.

                  (b) Lender and Borrower acknowledge and agree that the Covered
Intellectual Property is licensed by Borrower pursuant to the License Agreement
and that such License Agreement contains certain restrictions with respect to
the Covered Intellectual Property. Accordingly, notwithstanding anything in the
Security Documents to the contrary, the Collateral shall not include the Covered
Intellectual Property, any Product, the License Agreement or any of Borrower's
rights, title or interest (including, without limitation, any Contract Rights)
under the License Agreement. In furtherance of and not in limitation of the
foregoing: (i) neither the Collateral nor any component thereof shall include
any item or type of property (personal or real, tangible, intangible or
otherwise) in which the granting of a security interest is prohibited under the
License Agreement; (ii) the security interest granted hereunder is subordinate
in all respects to, and subject to, the rights of Wake Forest University under
the License Agreement (including, without limitation, any and all rights of Wake
Forest University thereunder to receive any royalties or other payments); and
(iii) the rights of Lender under this Agreement shall not conflict with,
diminish or otherwise adversely affect the rights of Wake Forest University
under the License Agreement. Borrower will not, by amendment of the License
Agreement or any other action taken after the date hereof, avoid or diminish or
seek to avoid or diminish the rights of Lender with respect to the Collateral.

                  (c) The security interest granted pursuant to this Agreement
shall terminate upon a Qualified Financing (as defined in the Loan Agreement),
in which event the Collateral shall be released and Lender shall promptly
deliver and execute or cause to be delivered and executed all termination
statements or other documents as Borrower may reasonably request to terminate
Lender's security interest in the Collateral.

         3. Representations and Warranties of Borrower. Borrower represents and
warrants to Lender as follows:

                  (a) The execution and delivery by Borrower of the Security
Documents, and the performance of the terms and obligations therein, are within
Borrower's corporate powers and have been duly authorized by all necessary
corporate action on the part of Borrower. The Security Documents, when executed
and delivered hereunder, will constitute valid and legally binding obligations
of Borrower enforceable against Borrower in accordance with their terms.

                  (b) No agreements or contracts relating to the Collateral are
in effect that would likely have a material adverse impact on Borrower's
business relating to the Collateral.

                                       3
<PAGE>

                  (c) Borrower is the owner of the Collateral and has good,
valid, marketable and insurable title to the Collateral, free and clear of all
Liens except for those in favor of Lender, subject to the terms of the License
Agreement.

                  (d) Except for the filing of financing statements with the
State of North Carolina and Forsyth County, North Carolina, and, only in the
case of any patent and trademark matters, filings with the United States Patent
and Trademark Office and, only in the case of any copyright matters, filings
with the United States Copyright Office, necessary to perfect the security
interests created hereunder, no authorization, approval, or other action by, and
no notice to or filing with, any governmental authority or regulatory body is
required either for the grant by Borrower of the security interest hereunder or
for the execution, delivery, or performance of this Agreement by Borrower or for
the perfection of such security interest or the exercise by Lender of its rights
hereunder to the Collateral. Upon the execution of this Agreement and the
completion of such filings, Lender will have a perfected, first priority
security interest in the Collateral.

                  (e) Neither the execution or delivery by Borrower of the
Security Documents, nor the performance of their respective terms and
obligations, will (i) violate Borrower's charter or bylaws, (ii) constitute a
breach or default under any agreement or instrument to which Borrower is a party
or by which Borrower is bound, which breach or default would have a material
adverse effect on Borrower; (iii) violate any applicable law, rule or
regulation, which violation would have a material adverse effect on Borrower, or
(iv) violate any order, writ, injunction, decree or judgment of any court or
governmental authority applicable to or binding upon Borrower, which violation
would have a material adverse effect on Borrower.

         4. Transfer and Other Liens. The provisions of Sections 6.02 and 6.04
of the Loan Agreement are hereby incorporated herein by reference.

         5. Other Financing Statements. Borrower represents, warrants and
covenants to and with Lender that: there exists no financing statement (or
similar statement or instrument of registration under the law of any
jurisdiction) covering or purporting to cover any interest of any kind in the
Collateral, and Borrower will not execute or authorize to be filed in any public
office any financing statement (or similar statement or instrument of
registration under the law of any jurisdiction) relating to the Collateral, as
applicable, except financing statements (or similar statements or instruments of
registration under the law of any jurisdiction) filed or to be filed in respect
of and covering the security interests granted to Lender by Borrower.

         6. Further Assurances.

                  (a) Borrower, upon request of Lender, will promptly deliver
and execute or cause to be delivered and executed, in form and content
satisfactory to Lender, any financing, continuation, termination, or security
interest filing statements, security agreement, assignment, or other document as
Lender may reasonably request in order to perfect, preserve, maintain, or
continue the perfection of Lender's security interest in the Collateral, or its
priority, including without limitation any document necessary to record Lender's
security interest in any state or county of any state, the United States Patent
and Trademark Office or the United States

                                       4
<PAGE>

Copyright Office. Borrower will pay the costs of filing any financing,
continuation, termination, or security interest filing statement, assignment or
other document as well as any recordation or transfer tax required by law to be
paid in connection with the filing or recording thereof.

                  (b) Borrower will, at its own expense, make, execute, endorse,
acknowledge, file and/or deliver to Lender from time to time such lists,
descriptions and designations of its Collateral, documents of title, vouchers,
invoices, schedules, confirmatory assignments, conveyances, financing
statements, transfer endorsements, powers of attorney, certificates, reports and
other assurances or instruments and take such further steps relating to the
Collateral and other property or rights covered by the security interest hereby
granted, which Lender deems reasonably appropriate or advisable to perfect,
preserve or protect its security interest in the Collateral.

         7. Power of Attorney. Borrower hereby appoints Lender as Borrower's
true and lawful attorney, with full power of substitution, to do any or all of
the following, in the name, place, and stead of Borrower, as the case may be:
(a) file this Agreement (or an abstract hereof) or any other document describing
Lender's interest in the Collateral with any appropriate governmental office
(including, without limitation, the State of North Carolina or any political
subdivision thereof and the United States Patent and Trademark Office or the
United States Copyright Office); and (b) following an Event of Default, (i)
endorse Borrower's name on all applications, documents, papers, and instruments
necessary for Lender to use or maintain the Collateral, as applicable; (ii) ask,
demand, collect, sue for, recover, impound, receive, and give acquittance and
receipts for money due or to become due under or in respect of any of the
Collateral; (iii) file any claims or take any action or institute any
proceedings that Lender may deem necessary or desirable for the collection of
any of the Collateral, or otherwise enforce Lender's rights with respect to any
of the Collateral; (iv) assign, pledge, convey, or otherwise transfer title in
or dispose of the Collateral, to any person; and (v) take any action and execute
any instrument that Lender may deem necessary or advisable to accomplish the
purposes of this Agreement.

         8. Right to Inspect. Borrower grants to Lender and its employees and
agents the right to visit Borrower's plants, corporate offices, and facilities
to inspect the Collateral at reasonable times during regular business hours with
prior written notice to Borrower.

         9. Name of Borrower, Place of Business, and Location of Collateral.
Borrower represents and warrants that its correct legal name is as specified on
the signature lines of this Agreement, and each legal or trade name of Borrower
for the previous seven (7) years (if different from Borrower's current legal
name) is as specified below the signature lines of this Agreement. Without the
prior written notice to Lender of at least thirty (30) days, Borrower will not
change its name, dissolve, merge, or consolidate with any other person. Borrower
represents and warrants that the address of its chief executive office is as
specified below the signature lines of this Agreement. The Collateral and all
books and records pertaining thereto will be located at Borrower's chief
executive office specified below. Borrower may establish a new location for the
Collateral or any part thereof, or the books and records concerning the
Collateral or any part thereof, only if (a) it shall have given to Lender prior
written notice of its intention so to do, clearly describing such new location
and providing such other information in connection

                                       5
<PAGE>

therewith as Lender may request, and (b) with respect to such new location, it
shall have taken all action satisfactory to Lender to maintain the security
interest of Lender in the Collateral intended to be granted hereby at all times
fully perfected and in full force and effect.

         10. Taxes. Borrower shall pay as and when due and payable all taxes,
levies, license fees, assessments, and other impositions levied on the
Collateral or any part thereof for its use and operations.

         11. Litigation and Proceedings. Borrower shall commence and diligently
prosecute in its own name, as the real party in interest, for its own benefit,
and at its own expense, such suits, administrative proceedings, or other actions
for infringement or other damages as are necessary to protect the Collateral.
Borrower shall provide to Lender any information with respect thereto reasonably
requested by Lender.

         12. Rights, Remedies and Agreements upon Event of Default.

                  (a) Borrower agrees that, if any Event of Default (as defined
in the Loan Agreement) shall have occurred and is continuing, then and in every
such case, Lender, in addition to any rights now or hereafter existing under
applicable law, and upon written notice to Borrower, shall have all rights as a
secured creditor under the Uniform Commercial Code in all relevant jurisdictions
and may:

                           (i) personally, or by agents or attorneys,
                  immediately take or retake possession of the Collateral or any
                  part thereof;

                           (ii) instruct the obligor or obligors on any
                  agreement, instrument or other obligation constituting the
                  Collateral to make any payment required by the terms of such
                  agreement, instrument or obligation directly to Lender;

                           (iii) sell, assign or otherwise liquidate, or direct
                  Borrower to sell, assign or otherwise liquidate, any or all of
                  the Collateral or any part thereof, and take possession of the
                  proceeds of any such sale or liquidation; and

                           (iv) take possession of the Collateral or any part
                  thereof by directing Borrower in writing to deliver the same
                  to Lender at any place or places designated by Lender; it
                  being understood that Borrower's obligation so to deliver the
                  Collateral is of the essence of this Agreement and that,
                  accordingly, upon application to a court of equity having
                  jurisdiction, Lender shall be entitled to a decree requiring
                  specific performance by Lender of said obligation.

                  (b) Borrower shall pay on demand all costs and expenses,
including, without limitation, reasonable attorneys' fees and expenses, incurred
by or on behalf of Lender (i) in enforcing the Obligations, and (ii) in
connection with the taking, holding, preparing for sale or other disposition,
selling, managing, collecting, or otherwise disposing of the Collateral. All of
such costs and expenses (collectively, the "Liquidation Costs") together with
interest thereon at the interest rate specified in the Note, from the date of
payment until repaid in full, shall be paid

                                       6
<PAGE>

by Borrower to Lender on demand and shall constitute and become a part of the
Obligations secured hereby. Any proceeds of sale or other disposition of the
Collateral will be applied by Lender to the payment of Liquidation Costs, and
any balance of such proceeds will be applied by Lender to the payment of the
remaining Obligations in such order and manner of application as Lender may
determine. Borrower hereby grants to Lender, as security for the full and
punctual payment and performance of the Obligations, a continuing security
interest in and lien on all now or hereafter existing balances, credits,
accounts, deposits, and all other sums credited by, maintained with, or due from
Lender or any affiliate of Lender to Borrower; and regardless of the adequacy of
any Collateral or other means of obtaining repayment of the Obligations, Lender
may at any time and without notice to Borrower set off the whole or any portion
or portions of any or all such balances, credits, accounts, deposits, and other
sums against any and all of the Obligations.

                  (c) If the sale or other disposition of the Collateral fails
to satisfy in full the Obligations, Borrower shall remain liable to Lender for
any deficiency.

                  (d) Borrower agrees that, if an Event of Default (as defined
in the Loan Agreement) shall have occurred and is continuing under Section
7.01(g) (regarding bankruptcy, etc.) or Section 7.01 (l) (regarding License
Agreement termination) of the Loan Agreement, then and in every such case,
Borrower, acting in good faith, shall (i) use commercially reasonable efforts to
cause Wake Forest University to license to Lender the Covered Intellectual
Property and such other rights with respect to the Product, including without
limitation the rights of Borrower under the License Agreement, as Lender may
reasonably request in order for Lender, in lieu of Borrower or any other party,
to commercialize and market the Product or (ii) in the case of Section 7.01(g)
but not 7.01(l), at the request of Lender, grant an exclusive sublicense to
Lender of all of Borrower's right, title and interest under the License
Agreement.

         13. Remedies Cumulative. Each right, power, and remedy of Lender as
provided for in this Agreement or now or hereafter existing at law or in equity
or by statute or otherwise shall be cumulative and concurrent and shall be in
addition to every other right, power, or remedy provided for in this Agreement
or now or hereafter existing at law or in equity or by statute or otherwise, and
the exercise or beginning of the exercise by Lender of any one or more of such
rights, powers, or remedies shall not preclude the simultaneous or later
exercise by Lender of any or all such other rights, powers, or remedies.

         14. Amendments, Etc. No amendment or waiver of any provision of this
Agreement, nor consent to any departure by Borrower herefrom, shall in any event
be effective unless the same shall be in writing and signed by Borrower and
Lender, and then such waiver or consent shall be effective only in the specific
instance and for the specific purpose for which given.

         15. Notices. All notices and other communications provided for
hereunder shall be in writing, shall specifically refer to this Agreement and
shall be deemed to have been sufficiently given to Borrower and Lender for all
purposes if mailed by first class certified or registered mail, postage prepaid,
express delivery service, personally delivered, or telecopied, to the following
names and addresses:

                                       7
<PAGE>

         If to Lender:

         PharmaBio Development Inc.
         4709 Creekstone Drive
         Riverbirch Bldg., Suite 200
         Durham, NC 27703
         Attention: Tom Perkins
         Facsimile: (919) 998-2090

         with a copy to:

         Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
         2500 First Union Capitol Center
         Raleigh, NC 27601
         Attention: Christopher B. Capel
         Facsimile: (919) 821-6800

         If to Borrower:

         Pilot Therapeutics, Inc.
         101 North Chestnut Street
         Albert Hall
         Winston-Salem, NC 27101
         Attention: Chief Executive Officer
         Facsimile: (336) 725-2221

         with a copy to:

         Womble Carlyle Sandridge & Rice, PLLC
         200 West Second Street
         Winston-Salem, NC 27101
         Attention: Peter A. Zorn
         Facsimile: (336) 726-6906

         16. No Waiver; Remedies. No failure on the part of Lender to exercise,
and no delay in exercising, any right hereunder or under the Loan Agreement or
the Notes shall operate as a waiver thereof; nor shall any single or partial
exercise of any such right preclude any other or further exercise thereof or the
exercise of any other right. The remedies herein provided are cumulative and not
exclusive of any remedies provided by law.

         17. Binding Effect; Assignment. This Agreement shall be binding upon
and inure to the benefit of Borrower and Lender and their respective successors
and assigns, provided that Borrower may not assign or transfer any or all of its
rights or obligations under the Security Documents without the prior written
consent of Lender, unless such an assignment or transfer is

                                       8
<PAGE>

effected in connection with the assignment or transfer of Borrower's rights and
obligations under the Loan Agreement as permitted thereunder, in which case no
such consent shall be required.

         18. Governing Law; Consent to Jurisdiction. This Agreement shall be
governed by, and construed in accordance with, the laws of the State of North
Carolina, without reference to the conflicts or choice of law principles
thereof. Borrower and Lender hereby irrevocably consent to the exclusive
personal jurisdiction of any state or federal courts located in North Carolina,
in any action, claim or other proceeding arising out of any dispute in
connection with the Security Documents, any rights or obligations hereunder or
the performance of such rights and obligations. Lender and Borrower agree to
waive their respective rights to a jury trial with respect to any action, claim,
or other proceeding arising out of any dispute in connection with the Security
Documents, any rights or obligations hereunder or thereunder, or the performance
of such rights and obligations.

         19. Severability. To the extent any provision of this Agreement is
prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this
Agreement.

         20. Entire Agreement. This Agreement, the other Security Documents, the
Loan Agreement and the Investment and Royalty Agreement between Borrower and
Lender embody the entire agreement and understanding between the parties hereto
and supersede all prior oral or written agreements and understandings relating
to the subject matter hereof. No statement, representation, warranty, covenant
or agreement of any kind not expressly set forth in the Security Documents or
the Loan Agreement shall affect, or be used to interpret, change or restrict,
the express terms and provisions of the Security Documents.

         21. Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original and all of which,
when taken together, shall constitute one and the same instrument.

              [THE REMAINDER OF THE PAGE IS INTENTIONAL LEFT BLANK;
                          SIGNATURES ON FOLLOWING PAGE]

                                       9
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Security
Agreement to be duly executed by their respective duly authorized officers, as
of the date first above written.

                                    BORROWER:

                                    PILOT THERAPEUTICS, INC.

                                    By:  /s/ Floyd H. Chilton
                                        -----------------------
                                    Name: Floyd H. Chilton
                                    Title: CEO

Legal or tradename of Borrower for the previous seven (7) years
---------------------------------------------------------------

Pilot Therapeutics, Inc.
Pilot Biotechnologies, Inc.
Pinnacle Biotechnologies, Inc.

Address of chief executive office of Borrower
---------------------------------------------

101 North Chestnut Street
Albert Hall
Winston-Salem, NC 27101

                                     LENDER:

                                     PHARMABIO DEVELOPMENT INC.

                                     By:  /s/ Tom Perkins
                                         -----------------------
                                     Name: Tom Perkins
                                     Title: VP & General Council

                                       10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]